Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

GrowPros Begins Permitting Process for Cannabis Facility

By Marketwired | January 14, 2016

GrowPros Cannabis Ventures Inc. has begun the permitting process with both the Local municipal and Quebec provincial governments in anticipation of beginning construction of the proposed 50,000 sq. ft. cannabis production facility for which an application under MMPR was submitted to Health Canada in November of 2014. The status of that application remains unchanged from our last update on October 1, 2015.

“As a company and in consultation with our major shareholders, we believe that proceeding with the construction of our production facility will place GrowPros in the strongest strategic position possible as the federal government continues to move into a period of regulatory restructuring of Canada’s Cannabis laws,” commented Ryan Brown, Chief Executive Officer.

GrowPros MMP, the wholly-owned subsidiary of GrowPros, has always maintained a vision of being a premier low cost wholesaler and supplier of cannabis to Canada’s legal cannabis industry. The application and facility plan were designed around low cost high quality production taking advantage of Quebec’s favourable operating costs and favourable climate for agricultural producers.

“Management believes that constructing a state of the art cannabis production facility in compliance with the current MMPR physical security and public safety regulations will provide GrowPros and its shareholders with a great asset moving forward,” commented Ryan Brown, Chief Executive Officer.

Update on Expected Proceeds from Cannabis Accelerators LTD (“CAL”)/Export Hydro Transaction

We have been notified that the proposed CAL/Export Hydro transaction will close late in the first quarter of 2016.

GrowPros is anticipating receiving $200,000 CDN and 1,000,000 stock options in the ASX listed public vehicle.

The expected receipt of these proceeds coincides with the Company’s expected first quarter’s capital requirements related to the start of the facility construction.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

MGS opens 300,000-square-foot Wisconsin facility to scale drug delivery device manufacturing
This is a Fujifilm Biotechnologies image of its northeast England campus.
Fujifilm Biotechnologies expands in U.K.
From automation islands to connected plants: A roadmap for pharma manufacturers
This is the logo of Johnson & Johnson.
Johnson & Johnson announces new North Carolina pharma plant
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE